LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

Search

REVOLUTION Medicines Inc

Atvērts

SektorsVeselības aprūpe

39.69 1.12

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

38.52

Max

40

Galvenie mērījumi

By Trading Economics

Ienākumi

-19M

-213M

EPS

-1.13

Darbinieki

616

EBITDA

-24M

-237M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+77.53% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

216M

7.8B

Iepriekšējā atvēršanas cena

38.57

Iepriekšējā slēgšanas cena

39.69

Ziņu noskaņojums

By Acuity

25%

75%

54 / 382 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 15. maijs 22:52 UTC

Peļņas
Galvenie tirgus virzītāji

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

2025. g. 15. maijs 20:37 UTC

Top Ziņas
Peļņas

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

2025. g. 16. maijs 00:00 UTC

Tirgus saruna

Xero Bull Stays Positive on Cost Outlook -- Market Talk

2025. g. 15. maijs 23:47 UTC

Tirgus saruna

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

2025. g. 15. maijs 23:38 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 15. maijs 23:38 UTC

Tirgus saruna

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

2025. g. 15. maijs 23:14 UTC

Top Ziņas

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

2025. g. 15. maijs 22:46 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025. g. 15. maijs 21:58 UTC

Peļņas

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

2025. g. 15. maijs 21:24 UTC

Peļņas

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

2025. g. 15. maijs 20:56 UTC

Tirgus saruna

U.S. Spending Downturn Could Lie Ahead -- Market Talk

2025. g. 15. maijs 20:54 UTC

Tirgus saruna
Peļņas

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

2025. g. 15. maijs 20:54 UTC

Peļņas

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

2025. g. 15. maijs 20:51 UTC

Peļņas

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

2025. g. 15. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 15. maijs 20:50 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

2025. g. 15. maijs 20:50 UTC

Peļņas

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

2025. g. 15. maijs 20:26 UTC

Top Ziņas

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

2025. g. 15. maijs 20:25 UTC

Peļņas

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

REVOLUTION Medicines Inc Prognoze

Cenas mērķis

By TipRanks

77.53% augšup

Prognoze 12 mēnešiem

Vidējais 70.09 USD  77.53%

Augstākais 80 USD

Zemākais 57 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi REVOLUTION Medicines Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

12

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

40.67 / 41.96Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

54 / 382 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.